NICOLA HANANIA to Risk Assessment
This is a "connection" page, showing publications NICOLA HANANIA has written about Risk Assessment.
Connection Strength
0.283
-
Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
Score: 0.096
-
Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
Score: 0.078
-
Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis. 2010 Oct 05; 5:357-66.
Score: 0.048
-
The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017 Nov 01; 18(11):955-959.e6.
Score: 0.019
-
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
Score: 0.016
-
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
Score: 0.014
-
Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May; 86(5):375-81.
Score: 0.012